Please select from the following list of abstracts, representing presentations given at Athens 2002 (IWWM-2) Session 9:

Targeting plasma cell dyscrasias in their bone marrow microenviroment. K.C. Anderson.

G3139 (BCL-2 antisense oligonucleotide) therapy in Waldenstrom's macroglobulinemia (WM): Laboratory evaluation of potential clinical efficacy. Gwen Nichols and Cy Stein.

G3139 (BCL-2 antisense oligonucleotide) therapy in Waldenstrom's Macroglobulinemia: targeted approach to enhance apoptosis. Stanley Frankel.

Dendritic cell mediated immunotherapy of Waldenstrom;s macroglobulinemia. Madhav Dhodapkar.

Novel biologically-basied therapies for Waldenstrom's macroglobulinemia (WM). C.S. Mitsiades, S.P. Treon, K.C. Anderson.

WSU-WM-SCID mouse xenograft model: utility in developing new therapeutic strategies in Waldenstrom's Macroglobulinemia (WM). Al-KatibAM, Aboukameel A, Mohammad RM.